for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Soligenix Inc

SNGX.OQ

Latest Trade

0.96USD

Change

0.04(+4.35%)

Volume

19,533

Today's Range

0.91

 - 

0.96

52 Week Range

0.65

 - 

2.20

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
0.92
Open
0.91
Volume
19,533
3M AVG Volume
4.17
Today's High
0.96
Today's Low
0.91
52 Week High
2.20
52 Week Low
0.65
Shares Out (MIL)
20.30
Market Cap (MIL)
19.49
Forward P/E
-2.04
Dividend (Yield %)
--

Next Event

Q3 2019 Soligenix Inc Earnings Release

Latest Developments

More

Soligenix Appoints Jonathan Guarino As Chief Financial Officer

Soligenix Announces Positive Recommendation On Its Phase 3 Clinical Trial For Treatment Of Oral Mucositis In Head And Neck Cancer

Soligenix Q2 Loss Per Share $0.12

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Soligenix Inc

Soligenix, Inc. is a late-stage biopharmaceutical company. The Company is focused on developing and commercializing products to treat rare diseases. The Company operates through two segments: BioTherapeutics and Vaccines/BioDefense. Its BioTherapeutics segment is developing a photodynamic therapy (SGX301) utilizing topical synthetic hypericin activated with safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL), formulations of oral beclomethasone 17,21-dipropionate (BDP) for the prevention/treatment of gastrointestinal (GI) disorders characterized by severe inflammation, and its innate defense regulator (IDR) technology, dusquetide (SGX942) for the treatment of oral mucositis in head and neck cancer. Its Vaccines/BioDefense business segment includes active development programs for RiVax, its ricin toxin vaccine candidate, OrbeShield, its GI acute radiation syndrome (GI ARS) therapeutic candidate, and SGX943, its melioidosis therapeutic candidate.

Industry

Biotechnology & Drugs

Contact Info

29 Emmons Dr Ste B10

+1.609.5388200

https://www.soligenix.com/

Executive Leadership

Christopher J. Schaber

Chairman of the Board, President, Chief Executive Officer

Jonathan Guarino

Chief Financial Officer, Senior Vice President

Oreola Donini

Senior Vice President, Chief Scientific Officer

Richard C. Straube

Senior Vice President and Chief Medical Officer

Daniel P. Ring

Vice President - Business Development and Strategic Planning

Key Stats

2.00 mean rating - 2 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.0K

2017

0.0K

2018

0.0K

2019(E)

0.0K
EPS (USD)

2016

-0.930

2017

-1.160

2018

-0.680

2019(E)

-0.490
Price To Earnings (TTM)
--
Price To Sales (TTM)
3.83
Price To Book (MRQ)
4.95
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-276.44
Return on Equity (TTM)
-113.78

Latest News

BRIEF-Soligenix Receives Orphan Drug Designation From The European Commission For Rivax For Prevention Of Ricin Poisoning

* SOLIGENIX RECEIVES ORPHAN DRUG DESIGNATION FROM THE EUROPEAN COMMISSION FOR RIVAX® FOR PREVENTION OF RICIN POISONING Source text for Eikon: Further company coverage:

BRIEF-Soligenix - Driving Towards Key Inflection Points With Two Pivotal Phase 3 Clinical Trials

* SOLIGENIX - DRIVING TOWARDS KEY INFLECTION POINTS WITH TWO PIVOTAL PHASE 3 CLINICAL TRIALS Source text for Eikon: Further company coverage:

BRIEF-Soligenix Announces US Patent Issuance For Use Of Dusquetide In Oral Mucositis

* SOLIGENIX ANNOUNCES US PATENT ISSUANCE FOR USE OF DUSQUETIDE IN ORAL MUCOSITIS Source text for Eikon: Further company coverage:

BRIEF-Soligenix Identifies Biomarkers For Ricin Toxin Vaccine Testing Under FDA Animal Rule

* SOLIGENIX IDENTIFIES BIOMARKERS FOR RICIN TOXIN VACCINE TESTING UNDER THE FDA ANIMAL RULE

BRIEF-‍Knoll Capital Management LP​ reports a 9.9 pct passive stake in Soligenix as of Nov 2

* Knoll Capital Management LP reports a 9.9 percent passive stake in Soligenix Inc as of Nov 2 - SEC Filing Source text: [http://bit.ly/2zVA43d] Further company coverage:

BRIEF-‍ACT Capital Management reports 9.9 pct passive stake in Soligenix - SEC filing​

* act Capital Management LLLP reports 9.9 percent passive stake in Soligenix Inc as of November 2, 2017 - SEC filing Source text: (http://bit.ly/2yFcZRO) Further company coverage: (Bengaluru Newsroom: +91 806 749 1136)

BRIEF-Soligenix reports Q3 loss per share $0.17

* Soligenix announces recent accomplishments and third quarter 2017 financial results

BRIEF-Soligenix Inc announces pricing of offering

* Soligenix announces pricing of $5,115,000 concurrent registered direct offering and private placement of common stock priced above market

BRIEF-Soligenix receives $1.5 mln to support Phase 3 clinical trial of SGX301​

* Soligenix - national Institutes of Health awarded co about $1.5 million over 2 years to support conduct of pivotal Phase 3 clinical trial evaluating SGX301 Source text: (http://bit.ly/2yemsz3) Further company coverage:

BRIEF-Soligenix announces $1.5 mln NIDCR SBIR grant award supporting the pivotal phase 3 clinical trial of SGX942

* Soligenix announces $1.5 million NIDCR SBIR grant award supporting the pivotal phase 3 clinical trial of SGX942 for the treatment of oral mucositis in head and neck cancer Source text for Eikon: Further company coverage:

BRIEF-Soligenix announces $1.5 mln NCI SBIR grant award supporting the phase 3 clinical trial of SGX301 for the treatment of cutaneous t-cell lymphoma

* Soligenix announces $1.5 million NCI SBIR grant award supporting the pivotal phase 3 clinical trial of SGX301 for the treatment of cutaneous t-cell lymphoma Source text for Eikon: Further company coverage:

BRIEF-Soligenix receives $2.5 mln in additional Niaid funding to advance development of heat stable ricin vaccine

* Soligenix receives $2.5m in additional Niaid funding to advance development of heat stable ricin vaccine

BRIEF-Soligenix reports Q2 loss per share $0.41

* Soligenix announces recent accomplishments and second quarter 2017 financial results

BRIEF-Soligenix Inc initiates pivotal phase 3 clinical trial of SGX942

* Soligenix initiates pivotal phase 3 clinical trial of sgx942 (dusquetide) for the treatment of oral mucositis in head and neck cancer patients

BRIEF-Soligenix gets NIAID funding for development of heat stable ricin vaccine

* Soligenix receives additional NIAID funding to advance development of heat stable ricin vaccine

BRIEF-Soligenix reports Q1 loss per share $0.32

* Soligenix announces recent accomplishments and first quarter 2017 financial results

BRIEF-Soligenix Inc receives Japanese patent for thermovax vaccine

* Soligenix Inc - soligenix receives Japanese patent for thermovax vaccine heat stabilization platform technology

BRIEF-Soligenix files for mixed shelf of up to $25 million

* Files for mixed shelf of up to $25 million - sec filing Source text for Eikon: Further company coverage:

BRIEF-Soligenix receives FDA protocol clearance of pivotal phase 3 clinical trial of sgx942

* Soligenix receives FDA protocol clearance of pivotal phase 3 clinical trial of sgx942 for the treatment of oral mucositis in head and neck cancer patients

BRIEF-Soligenix receives European patent for formulation of synthetic hypericin to treat psoriasis

* Soligenix Inc - Proprietary formulation of synthetic hypericin has been granted a European patent for treatment of psoriasis

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up